Recordati Industria Chimica E Farmaceutica S.p.A.(OTC) RCDTF

Recordati S.p.A. is a global pharmaceutical company headquartered in Milan, Italy, specializing in the research, development, production, and sale of pharmaceuticals. The company operates in various segments, including Specialty and Primary Care, and Rare Diseases, providing innovative treatments for a range of medical conditions.

Products and Services

• Specialty pharmaceuticals for rare diseases and complex conditions
• Primary care medications for chronic diseases like hypertension
• Innovative treatments for various therapeutic areas, including oncology and endocrinology

Growth Outlook

• Revenue of €696 million in Q2 2026, showing strong market demand
• Net income of €116 million in Q2 2026, reflecting effective cost management
• Consistent growth in specialty pharmaceuticals, driving future revenue potential

Financial Highlights

• Trailing twelve months (TTM) revenue of €2.8 billion, indicating robust performance
• Net profit margin of 18.4% TTM, showcasing operational efficiency
• Dividend yield of 2.54% TTM, appealing for income-focused investors

Recordati S.p.A. has established itself as a key player in the pharmaceutical industry, with a diverse portfolio of products that cater to both specialty and primary care markets. The company's focus on rare diseases positions it well for future growth, as these areas often have less competition and higher pricing power. Recent financial performance highlights a strong revenue base and profitability, which are critical indicators of the company's operational health. The consistent dividend yield further enhances its attractiveness to potential investors seeking stable returns. Overall, Recordati S.p.A. presents a compelling opportunity for those interested in the healthcare sector, particularly in innovative pharmaceutical solutions.